The immune system plays a significant role in multiple sclerosis. While MS was historically
thought to be T cell-mediated, multiple pieces of evidence now support the view that B cells …

Anti-CD20 therapies have demonstrated considerable efficacy in the treatment of relapsing
multiple sclerosis, constituting a high-efficacy treatment approach for reducing relapse risk …

Introduction: Featuring demyelination and axonal degeneration, multiple sclerosis (MS) is a
chronic autoimmune disease of the central nervous system representing a prominent cause …

Multiple sclerosis (MS) was previously thought to be a T-cell-mediated, demyelinating
disease of the central nervous system. Disease-modifying therapies targeting T cells have …

Multiple sclerosis (MS), which is a chronic inflammatory disease of the central nervous
system, still represents one of the most common causes of persisting disability with an early …

Until recently, in the pathogenesis of Multiple Sclerosis (MS), the contribution of B cells has
been largely underestimated, and the disease was considered a T-cell-mediated disorder …

Introduction: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous
system. The latest development of B-cell depletion by anti-CD20 monoclonal antibodies has …

Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and neurodegenerative
disease affecting the central nervous system (CNS), often characterized by the accumulation …

Selective depletion of CD20+ B cells by anti-CD20 monoclonal antibodies as monotherapy
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …

Several clinical trials have demonstrated the efficacy of lytic therapies targeting B cells in the
treatment of relapsing multiple sclerosis (MS). More modest efficacy has been noted in the …